Purchase this article with an account.
Despreaux Raphaelle, Sara Touhami, Clémence Virevialle, Raphaël Adam, Jean Philippe Nordmann, Jad Akesbi; DIABETIC MACULAR EDEMA IN NAIVE PATIENTS TREATED BY INTRAVITREAL OZURDEX IN CLINICAL PRACTICE: The “DIMENTION” Study.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):913.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the “real-life” efficacy and safety outcomes of intravitreal dexamethasone (DEX) implant as first line treatment in diabetic macular edema (DME).
Retrospective study of 31 consecutive patients (45 eyes) with DME treated by DEX implant as first-line therapy. Main outcome measures included the evolution of best-corrected visual acuity (BCVA) and central foveal thickness (CFT) overtime, retreatment interval and tolerance profile.
Overall, 2.53 ± 1.9 DEX implants were administrated over a 3-year follow-up period and 29 eyes (64.4%) received multiple injections (≥ 2). BCVA gains as compared to baseline values were +9.5 letters (p = 0.007), +15.4 letters (p = 0.03) and +9.9 letters (p = 0.18) respectively after 12, 24 and 36 months. Mean BCVA increased by an average of +7.8 letters (p < 0.0001), +5.8 letters (p = 0.004), +7.1 letters (p = 0.007) and +1.2 letters (p = 0.79) respectively 1, 3, 6 and 12 months after the latest DEX injection. Mean CFT decreased by -196.8 mm (p < 0.0001), -168.3 mm (p < 0.0001), - 97.6 mm (p = 0.006) and –41 mm (p = 0.27) respectively 1, 3, 6 and 12 months after the latest DEX injection. Seven eyes (15.6%) showed transient increase of intraocular pressure and 68% of phakic eyes underwent cataract surgery during the follow-up.
DEX implant allows long-term functional and anatomical improvement in naïve patients with DME with a good safety profile in real-life practice.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only